- Report
- October 2024
- 189 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- August 2024
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
- Report
- October 2024
- 198 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- July 2024
- 100 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- November 2021
- 243 Pages
Global
From €4230EUR$4,450USD£3,554GBP
- Report
- August 2023
- 114 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- January 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- January 2025
- 80 Pages
India
From €3327EUR$3,500USD£2,795GBP
- Report
- October 2023
- 83 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Book
- October 2012
- 1570 Pages

The Malaria Vaccine market is a subset of the larger Vaccines market. It is focused on the development and distribution of vaccines to prevent and treat malaria, a mosquito-borne infectious disease that affects millions of people worldwide. Vaccines are the most effective way to prevent malaria, and the market is driven by the need to reduce the burden of the disease.
The Malaria Vaccine market is composed of a variety of stakeholders, including pharmaceutical companies, research institutions, and public health organizations. These stakeholders collaborate to develop and distribute vaccines to those in need. Vaccines are typically administered through injection or oral administration, and are often combined with other preventative measures such as insecticide-treated bed nets and indoor residual spraying.
The Malaria Vaccine market is highly competitive, with a number of companies vying for market share. Some of the major players in the market include GlaxoSmithKline, Sanofi, Merck, and Pfizer. Show Less Read more